USPTO told to avoid negative focus on patent thickets
Pharma trade body highlighted negative narratives involving continuation patents | Such IP “essential for ongoing research and development” | USPTO requested comments following criticism of patent thickets.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
6 September 2022 Web page reveals information concerning patent term extension applications | President Joe Biden urged collaboration between USPTO and FDA.
22 April 2021 In a boon for eye care specialist Nicox, the United States Patent and Trademark Office has confirmed that one of its three patents covering a glaucoma treatment could be extended by up to five years.